Domperidone as an antiemetic in paediatric oncology.
Domperidone was evaluated as an antiemetic in the control of nausea and vomiting associated with the administration of cytotoxic chemotherapy for various malignancies in a paediatric population. The results indicate that it is an effective agent for this purpose, control having been reasonable or good in 47 of 58 drug trials. The optimum dose would appear to be 0.7 mg/kg per dose. The only toxicity noted was of pain at the site of intravenous administration if domperidone was not adequately diluted.
D000932:Antiemetics; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004294:Domperidone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009325:Nausea / Q000139:chemically induced
D000932:Antiemetics; D000970:Antineoplastic Agents; D004294:Domperidone